Overview We are a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. Our primary asset is mavorixafor, a small molecule delivered in a capsule for oral dosing as a selective antagonist of the chemokine receptor, CXCR4. We have one commercially approved product, XOLREMDI (mavorixafor), whic...
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-17 | 2025-12-31 | 0001501697-26-000018 | EDGAR | 86K words |
| 2025-03-26 | 2024-12-31 | 0001628280-25-014805 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0001628280-24-012578 | EDGAR | — |
| 2023-03-21 | 2022-12-31 | 0001628280-23-008745 | EDGAR | — |
| 2022-03-17 | 2021-12-31 | 0001628280-22-006547 | EDGAR | — |
| 2021-03-19 | 2020-12-31 | 0001628280-21-005202 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001628280-20-003484 | EDGAR | — |
| 2019-03-11 | 2018-12-31 | 0001564590-19-007097 | EDGAR | — |
| 2018-03-09 | 2017-12-31 | 0001564590-18-005038 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001501697-26-000068 | EDGAR | — |
| 2025-11-05 | 2025-09-30 | 0001501697-25-000043 | EDGAR | 21K words |
| 2025-08-08 | 2025-06-30 | 0001628280-25-039327 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0001628280-25-021358 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001628280-24-047445 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001628280-24-036127 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001628280-24-021120 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001628280-23-038334 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001628280-23-028897 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001628280-23-015763 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001628280-22-028201 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001628280-22-021070 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2025-11-05 | 0001501697-25-000041 | EDGAR | 2K words |
| 2025-10-27 | 0001501697-25-000032 | EDGAR | — |
| 2025-09-17 | 0001501697-25-000021 | EDGAR | — |
| 2025-08-25 | 0001501697-25-000008 | EDGAR | — |
| 2025-08-13 | 0001501697-25-000006 | EDGAR | — |
| 2025-08-12 | 0001628280-25-039770 | EDGAR | — |
| 2025-06-23 | 0001628280-25-032627 | EDGAR | — |
| 2025-06-11 | 0001628280-25-030743 | EDGAR | — |
| 2025-05-01 | 0001628280-25-021304 | EDGAR | — |
| 2025-04-24 | 0001628280-25-019507 | EDGAR | — |
214 total filings indexed. 183 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001501697 |
| Ticker | XFOR |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.x4pharma.com |
| Listed | 2017-11-16 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/XFOR (~200 tokens, structured JSON with cryptographic provenance)